Tag Archives: VODG

Vitro Biopharma CEO Letter to Shareholders 2015

11/5/15 VODG went up 121% today after posting this press release

OTCBB: VODG

Dear Shareholders:
Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation. The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only. Concussion is a growing issue within professional athletes including the NFL where significant health problems are derived from football-related concussion. Military service personnel and numerous others are also significantly impacted by TBI. We began development of stem cell activation technology and products during 2014 and expanded these activities in during 2015 to include treatment of concussion. We have developed patent-pending technology for treatment of neurological conditions through the activation of stem cells residing within the body. This is a process for administration of stem cell therapeutic benefit without stem cell transplants.

Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit

Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.

Pennyheaven Top Picks 2011

No Super 7 this year just my top three picks.
Prices reflect close of business 12/31/10.
Best of Luck and Wishing All of You a Very Happy and Prosperous New Year

1) International Dispensing Corporation IDND.PK .45

IDC is a research and development company that develops and manufactures cutting-edge dispensing solutions, and provides expert supply chain and consulting services, to the food-and-beverage and packaging industries. Its flagship product, The Answer® tap, enables aseptic liquid product to be dispensed from a flexible package over time without compromising the safety of the remaining contents, even without refrigeration.

For more information about IDC, please visit http://www.idcdispensing.com

Latest Quarterly Report: 9/30/2010

Latest News: IDC and PepsiCo Sign Agreement for The Answer

2) Vitro Diagnostics VODG .15

Vitro Diagnostics, Inc., dba Vitro Biopharma owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro also owns pending U.S. patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ assays for quality and potency determination of MSCs, ESC and iPSCs.

For more information about VODG please visit http://www.vitrobiopharma.com

Latest quarterly Report: 7/31/2010

Latest News: New Results Reveal Extensive Competitive Advantages of VitroGrow™ Stem Cell Culture Media

3) WebMediaBrands Inc WEBM 1.63

WebMediaBrands Inc. is an Internet media company that provides content, education, trade shows and online job board services to media and business professionals. The Company’s online business includes: (i) mediabistro.com, a leading blog network providing content, career and educational resources about major media markets and industry verticals including new media, social media, Facebook, TV news, advertising, public relations, publishing, design and mobile; (ii) SemanticWeb.com, providing industry leading content on Semantic Web technology; (iii) Brands of the World, Ads of the World, and other related websites, providing industry leading content for creative, advertising, and design professionals; and (iv) e-commerce websites including Freelance Connect and StockLogos.com. The Company’s trade show and educational offerings include conferences, online and in-person courses, and video subscription libraries on topics covered by the Company’s online business.

Latest quarterly Report: 9/30/2010

Latest News: WebMediaBrands Inc. Announces Plan to Repurchase Shares of Its Common Stock

DISCLAIMER, PLEASE READ

Please be advised that nothing within this notice shall constitute a solicitation or an offer to buy or sell any security mentioned herein. All statements made are our express opinion only and should be treated as such. Nothing within this notice should be considered personalized investment advice. Pennyheaven.com is neither a registered investment advisor nor affiliated with any broker or dealer. Any investments in stocks recommended in this notice should be made only after consulting with your investment advisor and only after reviewing the financial statements of the company. We reserve the right to trade in and out of these stocks at will, before, during, and/or after publication. We have not been compensated by any individual or company and we do not accept any paid promotion. Please do your own DD and trade only what is right for you.